Overview Press Releases Events and Presentations Financials and Filings Stock Information Corporate Governance FAQs Email Alerts Madrigal press releases are available below. Search them by keyword or browse by date. Year None202420232022202120202019201820172016 August 2, 2024 Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel July 24, 2024 Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024 June 6, 2024 Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress June 5, 2024 Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference May 29, 2024 Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress May 7, 2024 Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates April 24, 2024 Madrigal Statement on the Passing of Dr. Stephen Harrison April 23, 2024 Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 April 16, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) April 9, 2024 Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis Pagination Previous page Page 1 Current page 2 Page 3 Page 4 Next page
Madrigal press releases are available below. Search them by keyword or browse by date. Year None202420232022202120202019201820172016 August 2, 2024 Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel July 24, 2024 Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024 June 6, 2024 Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress June 5, 2024 Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference May 29, 2024 Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress May 7, 2024 Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates April 24, 2024 Madrigal Statement on the Passing of Dr. Stephen Harrison April 23, 2024 Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 April 16, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) April 9, 2024 Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis Pagination Previous page Page 1 Current page 2 Page 3 Page 4 Next page
July 24, 2024 Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
June 6, 2024 Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
June 5, 2024 Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 29, 2024 Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
May 7, 2024 Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
April 23, 2024 Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
April 16, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 9, 2024 Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
